止血診断薬市場：製品タイプ別、検査タイプ別、最終用途別-2025-2030年の世界予測

止血診断薬市場は、2023年に5億7,932万米ドルと評価され、2024年には6億2,010万米ドルに達すると予測され、CAGR 8.04%で成長し、2030年には9億9,577万米ドルに達すると予測されています。

止血診断薬市場の範囲には、血栓形成、血小板機能、凝固因子の検査など、止血障害の特定と管理を目的とした製品とサービスが含まれます。ヘルスケアシステムの重要な構成要素として、これらの診断薬は血友病、血栓症、その他の出血性疾患などの診断に不可欠です。その用途は病院、診断センター、研究機関、学術機関など多岐にわたり、最終用途には個々の患者の診断から大規模なスクリーニングプログラムまで含まれます。市場成長は、血液関連疾患の有病率の増加、ポイントオブケア検査のような技術の進歩、そのような疾患に罹患しやすい老年人口の増加によって影響を受けています。診断のスピードと精度を高めるために、AIを活用したデータ分析や個別化医療アプローチなど、新たな診断技術の開発と展開にビジネスチャンスが存在します。企業は、バイオテクノロジー企業やヘルスケアプロバイダーとの協力関係を模索し、こうした進歩を活用すべきです。しかし、診断ツールに関連する高コストや複雑な規制要件などの課題は、市場拡大を阻害する可能性があります。発展途上地域における認知度の限界や不十分なインフラは、潜在的な成長障壁をさらに強調しています。成長の可能性を最大化するために、企業は既存の検査の感度と特異度を向上させたり、迅速で信頼性の高い結果を提供する携帯型診断機器を考案するなどのイノベーションに注力することができます。最先端研究のための学術機関との連携や、診断精度を向上させるためのビッグデータの活用は、こうした機会を生かすために不可欠な戦略です。競合市場の情勢はダイナミックであり、規制状況や技術シフトを乗り切るための適応戦略を必要とするため、競争優位性を維持し、進化するヘルスケアのニーズに対応するためには、先見性のあるアプローチが必要となります。

市場力学：急速に進化する止血診断薬市場の主要市場インサイトを公開

止血診断薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の止血障害の増加
  • ポイントオブケア検査ソリューションへの傾斜
  • 止血障害に対する意識の高まりと早期診断の重視
• 市場抑制要因
  • 診断費用の高騰と製品回収の発生
• 市場機会
  • 個別化医療の活用によるオーダーメイド治療の実現
  • 止血診断法の進歩
• 市場の課題
  • 止血診断のための複雑な検査方法

ポーターのファイブフォース：止血診断薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：止血診断薬市場における外部からの影響の把握

外部マクロ環境要因は、止血診断薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析止血診断薬市場における競合情勢の把握

止血診断薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス止血診断薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、止血診断薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨止血診断薬市場における成功への道筋を描く

止血診断薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で止血障害の発生率が増加
    • ポイントオブケア検査ソリューションへの傾向
    • 止血障害に対する意識の高まりと早期診断の重要性
  • 抑制要因
    • 診断コストの高さと製品リコールの発生率
  • 機会
    • 個別化医療アプローチを活用し、患者に合わせた治療を提供する
    • 止血診断法の進歩
  • 課題
    • 止血診断のための複雑な検査方法
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 止血診断薬市場：製品別

• 消耗品
• ラボ用分析装置
• ポイントオブケア検査システム

第7章 止血診断薬市場テストタイプ別

• 活性化凝固時間
• 活性化部分トロンボプラスチン時間
• Dダイマー検査
• フィブリノーゲン検査
• 血小板凝集検査
• プロトロンビン時間（PT）検査

第8章 止血診断薬市場：最終用途別

• 在宅ケア環境
• 病院/診療所
• 独立診断研究所

第9章 南北アメリカの止血診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の止血診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの止血診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• ARUP Laboratories
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• Danaher Corporation
• DiaPharma Group, Inc.
• F. Hoffmann-La Roche Ltd.
• Grifols, S.A.
• Haemonetics Corporation
• Helena Laboratories Corporation
• HemoSonics, LLC
• HORIBA Group
• Laboratory Corporation of America Holdings
• Medtronic PLC
• Merck & Co., Inc.
• Randox Laboratories Ltd.
• Siemens AG
• Stago Group
• Sysmex America, Inc.
• Sysmex Europe SE
• Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH
• Thermo Fisher Scientific Inc.
• Werfen, S.A.

LIST OF FIGURES

• FIGURE 1. HEMOSTASIS DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. HEMOSTASIS DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. HEMOSTASIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. HEMOSTASIS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HEMOSTASIS DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. HEMOSTASIS DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY LABORATORY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY ACTIVATED CLOTTING TIME, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY ACTIVATED PARTIAL THROMBOPLASTIN TIME, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY D DIMER TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY FIBRINOGEN TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PLATELET AGGREGATION TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PROTHROMBIN TIME (PT) TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY HOSPITALS/CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY INDEPENDENT DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 32. CANADA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 33. CANADA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 34. CANADA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 49. CHINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 50. CHINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 51. CHINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 52. INDIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 53. INDIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 104. ITALY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 105. ITALY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 106. ITALY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 116. POLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 117. POLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 118. POLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 119. QATAR HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 120. QATAR HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 121. QATAR HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 149. HEMOSTASIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 150. HEMOSTASIS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Hemostasis Diagnostics Market was valued at USD 579.32 million in 2023, expected to reach USD 620.10 million in 2024, and is projected to grow at a CAGR of 8.04%, to USD 995.77 million by 2030.

The scope of the hemostasis diagnostics market encompasses products and services aimed at identifying and managing hemostatic disorders, including tests for blood clot formation, platelet function, and coagulation factors. As critical components of the healthcare system, these diagnostics are vital for diagnosing conditions such as hemophilia, thrombosis, and other bleeding disorders. Their applications extend across hospitals, diagnostic centers, research institutions, and academic settings, with an end-use scope that includes individual patient diagnostics and large-scale screening programs. Market growth is influenced by an increasing prevalence of blood-related disorders, advancements in technology like point-of-care testing, and a growing geriatric population susceptible to such conditions. Opportunities exist in the development and deployment of novel diagnostic technologies, such as AI-driven data analysis and personalized medicine approaches, to enhance diagnostic speed and accuracy. Businesses should explore collaborations with biotechnology firms and healthcare providers to leverage these advancements. However, challenges including high costs associated with diagnostic tools and complex regulatory requirements can impede market expansion. Limitations in awareness and inadequate infrastructure in developing regions further stress potential growth barriers. To maximize growth potential, companies could focus on innovations like improving the sensitivity and specificity of existing tests, or devising portable diagnostic devices that offer rapid, reliable results. Collaboration with academic institutions for cutting-edge research and leveraging big data to refine diagnostic precision are vital strategies for capitalizing on these opportunities. The nature of the hemostasis diagnostics market is dynamic and requires adaptive strategies to navigate regulatory landscapes and technological shifts, necessitating forward-thinking approaches to maintain competitive advantage and meet evolving healthcare needs.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hemostasis Diagnostics Market

The Hemostasis Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increase in incidences of hemostasis disorders worlwide
  • Inclination toward point-of-care testing solutions
  • Growing awareness of hemostasis disorders and emphasis on early diagnosis
• Market Restraints
  • High cost of diagnosis and incidences of product recall
• Market Opportunities
  • Utilization of personalized medicine approach to deliver tailored treatments
  • Advancements in diagnostic methods for hemostasis
• Market Challenges
  • Complex testing methods for hemostasis diagnosis

Porter's Five Forces: A Strategic Tool for Navigating the Hemostasis Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hemostasis Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hemostasis Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hemostasis Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hemostasis Diagnostics Market

A detailed market share analysis in the Hemostasis Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hemostasis Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hemostasis Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hemostasis Diagnostics Market

A strategic analysis of the Hemostasis Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hemostasis Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ARUP Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Danaher Corporation, DiaPharma Group, Inc., F. Hoffmann-La Roche Ltd., Grifols, S.A., Haemonetics Corporation, Helena Laboratories Corporation, HemoSonics, LLC, HORIBA Group, Laboratory Corporation of America Holdings, Medtronic PLC, Merck & Co., Inc., Randox Laboratories Ltd., Siemens AG, Stago Group, Sysmex America, Inc., Sysmex Europe SE, Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH, Thermo Fisher Scientific Inc., and Werfen, S.A..

Market Segmentation & Coverage

This research report categorizes the Hemostasis Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Consumables, Laboratory Analyzers, and Point-of-Care Testing Systems.
• Based on Test Type, market is studied across Activated Clotting Time, Activated Partial Thromboplastin Time, D Dimer Test, Fibrinogen Test, Platelet Aggregation Test, and Prothrombin Time (PT) Test.
• Based on End Use, market is studied across Home Care Setting, Hospitals/Clinics, and Independent Diagnostic Laboratories.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increase in incidences of hemostasis disorders worlwide
    • 5.1.1.2. Inclination toward point-of-care testing solutions
    • 5.1.1.3. Growing awareness of hemostasis disorders and emphasis on early diagnosis
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of diagnosis and incidences of product recall
  • 5.1.3. Opportunities
    • 5.1.3.1. Utilization of personalized medicine approach to deliver tailored treatments
    • 5.1.3.2. Advancements in diagnostic methods for hemostasis
  • 5.1.4. Challenges
    • 5.1.4.1. Complex testing methods for hemostasis diagnosis
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Hemostasis Diagnostics Market, by Product

• 6.1. Introduction
• 6.2. Consumables
• 6.3. Laboratory Analyzers
• 6.4. Point-of-Care Testing Systems

7. Hemostasis Diagnostics Market, by Test Type

• 7.1. Introduction
• 7.2. Activated Clotting Time
• 7.3. Activated Partial Thromboplastin Time
• 7.4. D Dimer Test
• 7.5. Fibrinogen Test
• 7.6. Platelet Aggregation Test
• 7.7. Prothrombin Time (PT) Test

8. Hemostasis Diagnostics Market, by End Use

• 8.1. Introduction
• 8.2. Home Care Setting
• 8.3. Hospitals/Clinics
• 8.4. Independent Diagnostic Laboratories

9. Americas Hemostasis Diagnostics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Hemostasis Diagnostics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Hemostasis Diagnostics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. ARUP Laboratories
• 3. Becton, Dickinson and Company
• 4. Bio-Rad Laboratories, Inc.
• 5. bioMerieux SA
• 6. Danaher Corporation
• 7. DiaPharma Group, Inc.
• 8. F. Hoffmann-La Roche Ltd.
• 9. Grifols, S.A.
• 10. Haemonetics Corporation
• 11. Helena Laboratories Corporation
• 12. HemoSonics, LLC
• 13. HORIBA Group
• 14. Laboratory Corporation of America Holdings
• 15. Medtronic PLC
• 16. Merck & Co., Inc.
• 17. Randox Laboratories Ltd.
• 18. Siemens AG
• 19. Stago Group
• 20. Sysmex America, Inc.
• 21. Sysmex Europe SE
• 22. Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH
• 23. Thermo Fisher Scientific Inc.
• 24. Werfen, S.A.